Dimerix (ASX:DXB) is a clinical-stage biopharmaceutical company with a portfolio of drug candidates for inflammatory diseases, including kidney and respiratory diseases. Dimerix’ lead clinical asset, DMX-200 or QYTOVRA®, is in Phase 3 trials as a treatment for focal segmental glomerulosclerosis (FSGS), a rare kidney disease with first interim analysis expected in March 2024.